Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-19
2011-07-19
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S234500, C514S252160, C514S265100, C540S524000, C544S117000, C544S280000
Reexamination Certificate
active
07981881
ABSTRACT:
Fused heterocylic compounds of the following Formulawherein R1, R2, R5, Z, J1and J2are described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.
REFERENCES:
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5527896 (1996-06-01), Wigler et al.
patent: 5726302 (1998-03-01), Ugarkar et al.
patent: 5733913 (1998-03-01), Blankley et al.
patent: 5733914 (1998-03-01), Blankley et al.
patent: 5977305 (1999-11-01), Wigler et al.
patent: 6028183 (2000-02-01), Lin et al.
patent: 0 767 172 (1997-04-01), None
patent: 0 861 836 (1998-09-01), None
patent: 1 201 765 (2000-05-01), None
patent: 2 009 145 (1989-09-01), None
patent: 58-150503 (1983-09-01), None
patent: WO 98/13350 (1998-04-01), None
patent: WO 98/33798 (1998-08-01), None
patent: WO 01/28987 (2001-04-01), None
patent: WO 01/44258 (2001-06-01), None
patent: WO 01/55148 (2001-08-01), None
patent: WO 01/64679 (2001-09-01), None
Han, P. et al., “Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart”, The Journal of Biological Chemistry, vol. 272, No. 26, pp. 16152-16157 (1997).
Henry, J.R. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24, No. 12, pp. 1345-1354 (1999).
Li, L. et al., “CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation”, Science, vol. 283, pp. 848-851 (1999).
Moreland, L.W. et al., “Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial”, Ann. Intern. Med., vol. 130, pp. 478-486 (1999).
Nakata, A. et al., “Potential role of phosphodiesterase 7 in human T cell function; comparative effects of two phosphodiesterase inhibitors”, Clin. Exp. Immunol., vol. 128, pp. 460-466 (2002).
Rankin, E.C.C. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, pp. 334-342 (1995).
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, pp. 807-823 (1999).
Sasaki, T. et al., “Identification of Human PDE7B, a cAMP-Specific Phosphodiesterase”, Biochemical and Biophysical Research Communications, vol. 271, pp. 575-583 (2000).
Barbosa Joseph
Guo Junqing
Pitts William J.
Bristol--Myers Squibb Company
Coleman Brenda L
Duncan Laurelee A.
Wang Ying
LandOfFree
Fused heterocyclic compounds and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterocyclic compounds and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649678